In recent years, the demand for pet healthcare has been growing steadily, and the development of pet drugs faces challenges such as high costs, long cycles, and high risks of failure. As a CRO/CDMO specializing in pet drug research and development, Protheragen Vetivio leverages over a decade of accumulated industry experience and resources to provide you with one-stop preclinical research services. We are committed to helping clients successfully transition from basic research to clinical studies, effectively advancing pet drug development and reducing associated risks. If you have any needs, please feel free to contact us.

Our Services

Protheragen Vetivio provides comprehensive preclinical research services for pet drugs, encompassing pharmacodynamics, pharmacokinetic studies, and safety evaluation. Leveraging our deep understanding of pet physiology, pathology, and disease, we have established a unique pet disease model platform and a rigorous GLP-compliant quality control system. Our services are designed to accurately predict drug effects in real-world clinical settings, significantly improving R&D success rates.

Dose-Range Finding Studies

We conduct systematic dose-ranging studies to determine the Minimum Effective Dose (MED) and Maximum Tolerated Dose (MTD) of candidate compounds, providing critical dose selection guidance for subsequent research.

Pharmacology Studies

We elucidate the mechanism of action (MOA) and therapeutic potential of candidate drugs in pets. Through in vitro and in vivo experiments, we systematically evaluate drug-target interactions and pharmacological effects, offering a scientific foundation for further studies.

• Canine Disease Model Evaluation
• Feline Disease Model Evaluation
• Others

Pharmacokinetics Studies

We investigate the absorption, distribution, metabolism, and excretion (ADME) of drugs in pets, as well as the relationship between drug exposure and efficacy/toxicity responses. This provides scientific support for optimizing dosing regimens and significantly enhances the success rate of subsequent clinical trials.

• Single-Dose Pk Study
• Metabolite Identification
• Repeated-Dose Pk Study
• Metabolic Pathway Study
• Tissue Distribution Study
• Plasma Protein Binding Determination

Toxicology Studies

In compliance with GLP standards, we comprehensively evaluate the potential toxicity of drugs in pets, determine their safety margins, and identify target organ toxicity. Our studies provide robust safety evidence to support clinical research.

• Acute Toxicity Study
• Chronic Toxicity Study
• Toxicokinetics (TK) Study
• Subacute Toxicity Study
• Genotoxicity Study
• Subchronic Toxicity Study
• Reproductive Toxicity Study

Process of Our Services

Why Choose Us?

Cross-Species Translation Experience

Our team possesses expertise in both human and veterinary drug research and development, enabling us to apply advanced concepts and technologies from human drug development to pet drug innovation. This unique cross-disciplinary perspective allows us to provide more innovative and practical solutions for our clients, accelerating the R&D process.

Specialized Disease Model Platform

We have established a pet disease model repository that more accurately predicts drug efficacy in real clinical settings based on pathological features and disease progression. This significantly enhances the success rate of clinical translation.

Rigorous Quality System

We have implemented a comprehensive quality management system, with all studies conducted in compliance with GLP standards.  From protocol design and experimental operations to data management, it undergoes strict quality control to ensure the reliability, integrity, and traceability of research data.

Client-Centric Collaboration Model

We understand the dynamic nature of pet drug R&D and offer flexible service models, avoiding a one-size-fits-all model. Each project is assigned a dedicated project manager to ensure seamless communication and precise implementation of client requirements.